News
After over a decade spent building Incyte up into a competitive commercial drugmaker, the company’s longtime CEO Hervé ...
The CDC’s Advisory Committee on Immunization Practices (ACIP) has blessed Merck’s new respiratory syncytial virus (RSV) shot ...
Vor Bio's surprise $4B revival deal for RemeGen's autoimmune drug triggers divergent stock reactions
For $45 million upfront, Vor Bio is gaining ex-China rights to RemeGen’s telitacicept, a first-in-class recombinant ...
A little less than a year after topping up its medical countermeasure contracts with Emergent BioSolutions, the federal ...
After blueprinting an injectables facility in North Carolina in 2020, it didn’t take long for Eli Lilly to draw up designs ...
U.S. multinational company Abbott entered a partnership with Abu Dhabi's Department of Health to manufacture medicines in the ...
While the first meeting of Robert F. Kennedy Jr.’s reshuffled Advisory Committee on Immunization Practices didn’t yield any ...
Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its effectiveness in another group of patients with the bleeding disorder. | ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback